Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi
Purpose of the study: Despite risk of hypersensitivity (HS), nevirapine (NVP) underpins first-line HIV therapy in Africa. The relationship between NVP exposure and HS is unknown but could be influenced by polymorphisms in CYP2B6 and CYP3A4 affecting drug metabolism. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P181 Cite this article as: Dickinson et al.: Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Journal of the International AIDS Society 2010 13(Suppl 4):P181. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112962/